<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129203</url>
  </required_header>
  <id_info>
    <org_study_id>VS-01</org_study_id>
    <nct_id>NCT04129203</nct_id>
  </id_info>
  <brief_title>Versi Retriever Approving Trial in Japan</brief_title>
  <official_title>Multi Center, Prospective, Registry Trial of Versi Retriever Mechanical Thrombecomy for Acute Ischemic Stroke in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kobe City General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kobe City General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is Versi Retriever mechanical thrombectomy device approving study in Japan. Multi
      center, single arm, prospective registry trial. Physicians control trial, conducted my N
      Sakai, Kobe City Medical Center General Hospital.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is Versi Retriever mechanical thrombectomy device approving study in Japan. Multi
      center, single arm, prospective registry trial. Physicians control trial, conducted my N
      Sakai, Kobe City Medical Center General Hospital.

      60 cases will be enrolled and 90 days follow up need. Primary endpoint is favorable clinical
      outcome, mRS 0-2. Secondary endpoint are mortality in 90days, immediate successful
      recanalization, TICI 2b-3, symptomatic intracranial hemorrhage, and any adverse event related
      to device and or procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Good clinical outcome</measure>
    <time_frame>90days after procedure</time_frame>
    <description>modified Rankin Score is 0-2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful recanalization</measure>
    <time_frame>at 3 passes of device in the procedure</time_frame>
    <description>TICI 2b-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful recanalization</measure>
    <time_frame>at end of procedure</time_frame>
    <description>TICI 2b-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic and asymptomatic intracranial hemorrhage</measure>
    <time_frame>at 24 hours after procedure</time_frame>
    <description>NIHSS 4 or more worsened</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good clinical outcome 2</measure>
    <time_frame>90days after procedure</time_frame>
    <description>mRS 0-2 or NIHSS 10 or more improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sever advers event</measure>
    <time_frame>90days after procedure</time_frame>
    <description>device or procedure related</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Stroke, Acute</condition>
  <arm_group>
    <arm_group_label>Trial arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mechanical thrombectomy using Versi Retriever</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Versi Retriever thrombectomy</intervention_name>
    <description>Mechanical thrombectomy using Versi Retriever</description>
    <arm_group_label>Trial arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  acute onset neurological sympto m related to occluded vessel

          -  within 8 hours from onset to tre atment or within 24 hours from onset to treatment
             with imaging diagnosis

          -  contra-indication or failed to int ravenous rt-PA

          -  accessible occlusion at ICA, MC A, VA, BA, PCA

          -  5-30 of NIHSS

          -  0-2 of mRS before onset

          -  obtain documented informed co ntent

        Exclusion Criteria:

          -  following condition; arterial diss ection, engird, inaccessible turtuousity, difficult
             access by 50% or m ore stenosis, acute intracranial hemorrhage, space occuping lesion
             or brain tumor, major early ischemic change in brain

          -  occlude 2 major vessel territory

          -  allege for contrast media,

          -  abnormal PTT/APTT within 4 h ours intravenous heparin

          -  hemorrhagic tendency or 3 or more INR with Warfarin administration

          -  30000cc or less of Platelet

          -  50mg/dL or less of blood sugar

          -  uncontrolled blood pressure, 185mmHg or more at systolic, 110m mHg or more at
             diastolic

          -  90days or less life expancy

          -  pregnant or lactating

          -  join another trial of medicine or medical device

          -  ineligible for trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nobuyuki Sakai, MD DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Kobe City Medical Center General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nobuyuki Sakai, MD DMSc</last_name>
    <phone>81783024321</phone>
    <phone_ext>080</phone_ext>
    <email>n.sakai@siren.ocn.ne.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chiaki Sakai, MD PhD</last_name>
    <phone>81783024321</phone>
    <email>chiakimk@cronos.ocn.ne.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nobuyuki Sakai, MD, DMSc</last_name>
      <phone>81783024321</phone>
      <phone_ext>080</phone_ext>
      <email>n.sakai@siren.ocn.ne.jp</email>
    </contact>
    <contact_backup>
      <last_name>Chiaki Sakai, MD PhD</last_name>
      <phone>81783024321</phone>
      <email>chiakimk@cronos.ocn.ne.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Yasushi Matsumoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuji Matsumaru, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shinichi Yoshimura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kobe City General Hospital</investigator_affiliation>
    <investigator_full_name>Nobuyuki Sakai</investigator_full_name>
    <investigator_title>Director, Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>acute ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

